Background: Sotalol is a class III antiarrhythmic drug commonly used in various arrhythmia treatments. However, due to its potent potassium channel inhibition, it can prolong the QT interval and lead malignant arrhythmias. Empagliflozin an inhibitor of sodium‑glucose cotransporter 2 (SGLT2) has positive effect on cardiovascular outcomes. Since empagliflozin activation channels unknown, there no...